glp-1 receptor agonist mechanism Agonists as Treatments for Type 2 Diabetes Mechanisms of GLP-1 Receptor Agonist-Induced
Description
Results Seven trials (6609 participants) were included
The real problem seems to be retention
Understand about the investigational Alluvi Retatrutide 40 mg injection a GLP-1 + GIP + Glucagon triple-agonist studied for obesity
Here, we aimed to provide an overview of retatrutide's safety and effectiveness in treating obesity.
Both human and animal studies reported inconsistent BP response to acute administration but showed hypotensive effect of chronic administration of GLP-1/ GLP-1 RAs
